TOPLINE: A recent analysis indicated that switching from the standard-dose inactivated influenza vaccine to the recombinant influenza vaccine (RIV) could have prevented nearly 100,000 hospitalizations among working-age adults in the United States over 10 seasons. The greatest benefits would have been seen in individuals aged 50-64 years and at-risk adults aged 18-49 years with chronic …
Leave a Comment Leave a Comment
